Ribavirin therapeutic drug monitoring: why, when and how?
Version of Record online: 24 SEP 2009
© 2009 The Authors Journal compilation © 2009 Société Française de Pharmacologie et de Thérapeutique
Fundamental & Clinical Pharmacology
Volume 24, Issue 4, pages 401–406, August 2010
How to Cite
Stanke-Labesque, F., Loustaud-Ratti, V., Babany, G., Gagnieu, M.-C., Marquet, P. and The French Ribavirin Group OPTIRIB (2010), Ribavirin therapeutic drug monitoring: why, when and how?. Fundamental & Clinical Pharmacology, 24: 401–406. doi: 10.1111/j.1472-8206.2009.00778.x
- Issue online: 6 JUL 2010
- Version of Record online: 24 SEP 2009
- Received 27 February 2009; revised 1 July 2009; accepted 3 September 2009
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.